TCTiffany W. Chow

Tiffany W. Chow

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tiffany W. Chow has a total of 84 co-authors. Here are the top co-authors by number of shared publications:

  • Sandra Elizabeth Black

    Dr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, 2075 Bayview Avenue, 416-480-6100, Ect. 85409, Toronto, ON, Canada

    9 shared publications
  • Joel Ramirez

    Dr. Sandra E. Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada

    5 shared publications
  • Sylvain Houle

    Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada

    5 shared publications
  • Donald T. Stuss

    Division of Neurology, Rotman Research Institute, Baycrest, Toronto, ON, Canada, University of Toronto, Toronto, ON, Canada

    4 shared publications
  • Morris Freedman

    Division of Neurology, Baycrest

    4 shared publications
  • Malcolm A. Binns

    Rotman Research Institute, Baycrest Centre, Toronto, ON, Canada

    3 shared publications

Latest Publications

  • PIB-Positive PET in Individuals with Early- but Not Late-Onset Frontotemporal Dementia

    by Eric E. Brown, Ariel Graff-Guerrero, Sylvain Houle, Alan Wilson, Zahinoor Ismail, Bruce G. Pollock, Benoit H. Mulsant, David F. Tang-Wai, Nicolaas P. Verhoeff, Morris Freedman, et al.

  • A case of apathy due to frontotemporal dementia responsive to memantine.

    by Kira A. Links, Sandra E. Black, Ariel Graff-Guerrero, Alan A. Wilson, Sylvain Houle, Bruce G. Pollock, Tiffany W. Chow

    To study the effect of memantine on apathy, a common symptom of behavioral variant frontotemporal dementia (bvFTD).


  • A case of semantic variant primary progressive aphasia with severe insular atrophy

    by T. W. Chow, K. A. Links, D. L. Masterman, M. F. Mendez, H. V. Vinters

    Insular degeneration has been linked to symptoms of frontotemporal dementia (FTD). Presented in this case is a patient exhibiting semantic variant primary progressive aphasia, behavioral disturbance. Upon autopsy, he was found to have severe insular atrophy. In addition, selective serotonin reuptake inhibitors were ineffective in reducing symptoms of obsessive–compulsive behaviors or emotional blunting. This case suggests that Seeley et al.'s (2007 Seeley, W. W. , Allman, J. M. , Carlin, D. A. and et al. 2007. Divergent social functioning in behavioral variant frontotemporal dementia and Alzheimer disease: Reciprocal networks and neuronal evolution. Alzheimer Disease & Associated Disorders, 21: S50–S57. [Crossref], [PubMed], [Web of Science ®] , [Google Scholar] , Alzheimer Disease & Associated Disorders, 21, S50) hypothesis that von Economo neurons and fork cell-rich brain regions, particularly in the insula, are targeted in additional subtypes of FTD beyond the behavioral variant.


  • Fluorodeoxyglucose positron emission tomography in semantic dementia after 6 months of memantine: an open‐label pilot study

    by Tiffany W. Chow, David Fam, Ariel Graff‐Guerrero, Nicolaas P. G. Verhoeff, David F. Tang‐Wai, Mario Masellis, Sandra E. Black, Alan A. Wilson, Sylvain Houle, Bruce G. Pollock

    Objectives: To follow up on the increases we reported in normalized metabolic activity in salience network hubs from a 2‐month open‐label study of memantine in frontotemporal dementia (FTD).Methods: We repeated fluorodeoxyglucose positron emission tomography (FDG‐PET) after 6 months of drug use and subjected the data to Statistical Parametrical Mapping (SPM) analysis to reveal clusters of significant change from baseline. We also sought correlations between changes in behavioral disturbances on the Frontal Behavioral Inventory (FBI) and the PET signal.Results: Recruitment of one progressive nonfluent aphasia and one behavioral variant FTD precluded statistical analysis for any FTD subtype other than semantic dementia (SD). The baseline‐to‐6‐month interval showed increased normalized metabolic activity in the left orbitofrontal cortex (p < 0.002) for five participants with SD. The 2–6‐month interval revealed a late increase in normalized metabolic activity in the left insula (p < 0.013), right insula (p < 0.009), and left anterior cingulate (p < 0.005). The right anterior cingulate showed both an initial increase and a delayed further increase (2–6 months, p < 0.016). FBI scores worsened by 43.3%. One participant with SD opted not to continue memantine beyond 2 months yet showed similar FDG‐PET increases.Conclusions: Increases in normalized cortical metabolic activity in salience network hubs were sustained in SD over a 6‐month period. Because one participant without medication also showed these changes, further investigation is recommended through a double‐blind, placebo‐controlled study with FDG‐PET as an outcome measure. Copyright © 2012 John Wiley & Sons, Ltd.


  • Open Access

    Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia

    by Tiffany W Chow, Nicolaas Plg Verhoeff, Sandra Black, Bruce G Pollock, Graff- Guerrero, Binns, Tang- Wai, Morris Freedman, Mario Masellis, Wilson, et al.

    Background: Memantine has shown effects on cortical metabolism in Alzheimer's disease (AD), and the mechanism of action may not be specific to AD alone. We hypothesized that participants with frontotemporal dementia taking memantine would show an increased cortical metabolic activity in frontal regions, temporal regions, or in salience network hubs. Methods: Sixteen participants with behavioral or language variant frontotemporal dementia syndromes (FTD) were recruited from tertiary FTD clinics and treated with memantine hydrochloride 10 mg twice daily in this fixed-dose, open-label pilot study. The primary endpoint was enhancement of cortical metabolic activity after 7–8 weeks of treatment. Secondary endpoints were measures of mood and behavior disturbance, frontal executive function, and motor disturbance. Results: Voxel-wise parametric image analysis of positron emission tomography (PET) data from seven behavioral variant FTD patients, eight semantic dementia patients, and one progressive nonfluent aphasia patient, of mean age 64.3 years, mean duration of illness 4.25 years, and baseline mean sum of boxes Clinical Dementia Rating score 6.59, revealed an increase in [18F]-fluorodeoxyglucose (FDG) normalized metabolic activity in bilateral insulae and the left orbitofrontal cortex (P < 0.01). The increase on FDG-PET did not correlate with changes on behavioral inventories. Post hoc analysis indicated that semantic dementia participants drove this finding. Conclusion: This open-label clinical PET study suggests that memantine induces an increase in metabolism in the salience network in FTD. A placebo-controlled follow-up study is warranted.


  • Open Access

    Visual Rating versus Volumetry to Detect Frontotemporal Dementia

    by T.W. Chow, F. Gao, K.A. Links, J.E. Ween, D.F. Tang-Wai, J. Ramirez, C.J.M. Scott, M. Freedman, D.T. Stuss, S.E. Black

    Background/Aims: Automated, volumetrically defined atrophy in the left anterior cingulate (LAC) and anterior temporal regions (LAT) on MRI can be used to distinguish most patients with frontotemporal dementia (FTD) from controls. FTD and Alzheimer’s disease (AD) can differ in the degree of anterior temporal atrophy. We explored whether clinicians can visually detect this atrophy pattern and whether they can use it to classify the 2 groups of dementia patients with the same accuracy. Methods: Four neurologists rated atrophy in the LAC and LAT regions on MRI slices from 21 FTD, 21 controls, and 14 AD participants. Inter-rater reliability and diagnostic accuracy were assessed. Results: All 4 raters agreed on the presence of clinically significant atrophy, and their atrophy scoring correlated with the volumes, but without translation into high inter-rater diagnostic agreement. Conclusions: Volumetric analyses are difficult to translate into routine clinical practice.


  • What Are the Different Initial Presentations of Frontotemporal Dementia?

    by Tiffany W. Chow

    Frontotemporal dementia (FTD) symptoms at the beginning of illness are in either the realm of behavioral disturbance or in language disruption, also known as aphasia. Based on specific constellations of behavioral change or characteristics of the aphasia, physicians can anticipate the type of protein that is abnormal in the brain. Family history rich with similar instances of illness can further guide the cause of illness in an individual. Knowing the type of protein abnormality (proteinopathy) from among the three most common in FTD (tau, TDP-43, or fused in sarcoma) can help treating clinicians to advise families on the future course of illness and future clinical drug trials that would be most applicable to each patient.


  • Open Access

    A Brief History of Research in Frontotemporal Dementia (and Celebration of Bruce Miller's Impact on it)

    by Chow Tiffany

    Pick’s disease was first described in the 1930s. Further clinical and neuropathological information about frontotemporal dementia did not come to light until the 1970s. And since then, the frontotemporal dementias, whether one considers the behavioral or the language presentations, make a wonderful substrate for the learning objectives of this conference. They present an amazing opportunity to study the anatomy & pathophysiology of frontal lobe function & dysfunction, the expression of frontal lobe function and dysfunction across maturational stages, cover the breadth of the frontal lobe function from cognitive to emotional, and clearly show the roles of the frontal lobes in neuropsychiatric disorders. In the 60s, the Haight in San Francisco had no idea that Drs. Stan Prusiner and Bruce Miller would be on their way, setting up labs that would impact neurodegenerative disease and international collaboration to forward that research. Dementia was mostly considered to be "senile dementia," and age-related phenomenon generally a tribute to hardening of the arteries. The 70s saw a handful of publications regarding presenile dementias or the odd case report about patients who would later be described as primary progressive aphasia. It was in the mid-1980s that the national Institute on aging funded the Alzheimer's Disease Research Centers. The Lund and UCLA groups introduced a new type of pathology in dementia, that of the frontotemporal type. In the 90s, things took off, with more centers around Europe and North America describing cases. Bruce Miller began to convene colleagues at Harbor-UCLA, creating his first multidisciplinary team to approach the evaluation of these patients. Family histories were examined closely, and Chromosome 17 and the region expressing tau are elucidated as playing an important role in the disease. Cortical basal syndrome, progressive supranuclear palsy, and ALS are brought into the circle of frontotemporal dementias. The next decade brought funding for multicenter data collection and broader recognition of this dementing illness by lay public. Volumetric studies cropped up like clover, but visual rating by clinicians has not yet matched the discrimination accuracy of the software. Progranulin and TAR DNA binding protein-43 were added to the list of proteinopathies associated with frontotemporal dementia. Information on mutations associated with frontotemporal dementias exceeds the proportion of Alzheimer's disease cases that have a clear genetic association. The latest decade has brought the dawning of networks approaches that map cleanly onto the distribution of von Economou neurons. Fused in sarcoma protein creates another explanation for ubiquitin immunoreactive inclusions. The Alzheimer's Disease Neuroimaging Initiative offers public access to centers with smaller populations of FTD patients to conduct their own analyses on a large uniform data set. Treatment, however, remains elusive. At best, there is symptomatic treatment. Some equal local transient behavioral benefit is noted with memantine. Clinicaltrials.gov shows 20 studies actively recruiting subjects with frontotemporal dementia.

  • Alzheimer's disease neuropathologic changes in semantic dementia

    by Tiffany W. Chow, Arousiak Varpetian, Taryn Moss, Harry V. Vinters, Stefanie Marquez, Carol Miller

    Neuropathologic change underlying primary progressive aphasia (PPA) most commonly includes one of the frontotemporal lobar degenerations, such as FTLD-tau or FTLD-ubiquitin. The next most frequent etiology of PPA is Alzheimer's disease (AD). We describe 5 subjects with clinical diagnoses of semantic dementia, who underwent longitudinal clinical evaluation and postmortem neuropathology examination of the central nervous system. This case series examines retrospectively which clinical parameters might have pointed to the neuropathological diagnosis of AD. Conclusion: family history of late onset dementia, APOEε4 status, combined features of semantic dementia and progressive non-fluent aphasia present early in illness, or generalized seizures, may indicate AD as the underlying pathology of semantic dementia.


  • Apathy Is Not Associated with Basal Ganglia Atrophy in Frontotemporal Dementia

    by Kira A. Links, Tiffany W. Chow, Malcolm Binns, Morris Freedman, Donald T. Stuss, Chris J.M. Scott, Joel Ramirez, Sandra E. Black